Enzymatica: Nothing to sneeze at - Redeye

Redeye initiates coverage of Enzymatica, a Swedish commercial-stage medtech company offering ColdZyme for treating, alleviating, and shortening the duration of a cold. Its establishment in the Swedish market, followed by an ongoing global expansion with well-known distribution partners, offers a compelling case, where we expect a sales CAGR of 59% between 2022-2026e.

Länk till analysen i sin helhet: https://www.redeye.se/research/867634/enzymatica-nothing-to-sneeze-at?utm_source=finwire&utm_medium=RSS